GlassScriptPhysician profile
Ruchi P Moore
NPI 1013020775
$1,241.68
in general payments reported to CMS, 2019-2025
21 companies · $246 in 2025
The $246 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $88.70 · 2020: $71.57 · 2021: $54.31 · 2022: $251 · 2023: $234 · 2024: $297 · 2025: $246.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $776.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $776.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $233.86 | 2019-2024 | |
| Astellas Pharma US INC | $182.58 | 2022-2025 | Veozah |
| Sumitomo Pharma America, INC. | $121.88 | 2023-2025 | Myfembree |
| Bayer Healthcare Pharmaceuticals INC. | $88.01 | 2020-2025 | |
| Biogen, INC. | $80.78 | 2024-2025 | Zurzuvae |
| Pfizer INC. | $76.13 | 2019-2024 | |
| Applied Medical Resources Corporation | $58.18 | 2023 | |
| Hologic Sales and Service, LLC | $54.79 | 2023-2025 | Aptima, Thinprep 2000 Processor, Myosure Tissue Removal Device |
| Exeltis, USA INC. | $53.33 | 2024-2025 | Slynd |
| Myovant Sciences INC. | $53.27 | 2022 | |
| Mayne Pharma Commercial LLC | $51.49 | 2022-2025 | |
| Millicent US INC | $44.88 | 2024-2025 | Intrarosa, Femring |
| Minerva Surgical, INC | $42.34 | 2020 | |
| Coopersurgical, INC. | $19.71 | 2024 | Paragard T 380a |
| Organon LLC | $16.46 | 2023 | Nexplanon |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $16.02 | 2025 | The Cologuard Plus Collection Kit |
| Aspira Women'S Health INC | $14.37 | 2024 | Ova1 |
| Merck Sharp & Dohme LLC | $11.45 | 2019 | |
| Channel Medsystems, INC. | $11.23 | 2025 | |
| Daiichi Sankyo INC. | $10.92 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$5.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ruchi Moore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.